Antimicrobial Treatment of Lower Respiratory Tract Infections
A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antibiotic Therapy in Infectious Diseases".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 22216
Special Issue Editors
Interests: inflammation; endothelial injury; ventilator associated pneumonia; critical care medicine; critical care infections; SARS-CoV-2
Interests: infections; emerging pathogens; inflammation; immunology; public health; respiratory infections; MDR organisms; viral pathogens
Interests: viral infections; immunopathogenesis of viral disease
Special Issues, Collections and Topics in MDPI journals
Interests: HIV infection; viral infection; emerging pathogens; MDR organisms; respiratory infections; infections in immunocompromised; host immune responses
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to invite you to contribute to this Special Issue, entitled “Antimicrobial Treatment of Lower Respiratory Tract Infections”. Lower respiratory tract infections (LRTIs) are highly prevalent. However, severe LRTIs are associated with significant mortality and morbidity worldwide. Pneumonia remains among the main causes of morbidity and mortality in adults and represents the leading cause of death in children under the age of five. Pneumonia, and specifically severe community-acquired pneumonia and nosocomial pneumonia, as well as other severe LRTIs, are associated with huge socioeconomic and healthcare costs. Antimicrobials remain the mainstay of bacterial LRTI treatment, although their use in viral LRTIs may be associated with significant side effects. Prompt initiation of pathogen-specific antimicrobials is crucial for improving the prognosis and outcome of LRTIs and plays a pivotal role in reducing their global healthcare and socioeconomic burden.
This Special Issue aims to delineate the latest pre-clinical (experimental), animal and clinical research and clinic-epidemiological data on the role of old and newer antimicrobials in the progress, prognosis and the outcome of pneumonia. Ultimately, this issue aims to expand our understanding and generate in-depth knowledge on the management of community- and healthcare-associated bacterial LRTIs through gathering current evidence and addressing potential gaps in the literature.
Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: antimicrobial treatment in community-acquired pneumonia/lower respiratory tract infection; antimicrobial treatment in healthcare-associated pneumonia; epidemiology and mechanisms of antibiotic resistance of pneumonia pathogens; novel antibiotics for lower respiratory tract infections; use of antimicrobials for lower respiratory tract infections in specific populations, such as immunocompromised and critically ill patients, those with COVID-19 and other severe viral LRTIs and elderly, pediatric, cystic fibrosis, COPD and asthma patients.
We look forward to receiving your contributions.
Prof. Dr. Anastasia Kotanidou
Prof. Dr. Sotirios Tsiodras
Dr. Paraskevi C. Fragkou
Guest Editors
Dr. Charalampos D. Moschopoulos
Guest Editor Assistant
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lower respiratory tract infection
- community-acquired pneumonia
- nosocomial pneumonia
- ventilator-associated pneumonia
- antibiotics
- antimicrobial resistance
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: The role of the respiratory microbiome in the pathogenesis of aspiration pneumonia: implications for diagnosis and potential therapeutic choices
Author: Vallianou
Highlights: * The lungs of human beings are not sterile.
* The human lung microbiome can be determined by the use of sophisticated molecular techniques.
* It seems that the human lung microbiome could play a crucial role in aspiration pneumonia.
*Therapeutic choices should be expanded to cover multi-drug resistant gram negative bacteria in selected cases of aspiration pneumonia.